K.V.N. Naik S.P. Sanstha's Polytechnic

Electric Buses Global Market Report 2022: Aggressive Government Initiatives Fuel Adoption Worldwide - ResearchAndMarkets.com

Retrieved on: 
Monday, March 20, 2023
Public Transport, EV, Electric Vehicles, Transport, Automotive, Solaris, Maintenance, BYD Company, K.V.N. Naik S.P. Sanstha's Polytechnic, IVECO, Volvo, FAW Group, Mercedes-Benz Group, CO2, Air pollution, Environment

The electric buses market worldwide is expected to grow with a CAGR of 22.9% during the forecast period.

Key Points: 
  • The electric buses market worldwide is expected to grow with a CAGR of 22.9% during the forecast period.
  • Of these, electric buses are expected to emerge as the most promising segment due to ongoing government initiatives across the world.
  • Currently, China has more than 350,000 electric buses in its public transport fleet, making it the largest market for electric buses.
  • In 2021, pure electric buses segment accounted for larger share as compared to hybrid electric buses segment.

Four Global Firms Shortlisted for Egypt’s $2 Billion Industrial Project

Retrieved on: 
Tuesday, August 23, 2022
Chemicals, Plastics, Commercial Building & Real Estate, Construction & Property, Manufacturing, FEED, Engineering, General authority, GDP, EPC, James McHugh Construction Co, Investment, USD, HDEC, Leonardo S.p.A., Intention, General Authority for Entertainment (Saudi Arabia), K.V.N. Naik S.P. Sanstha's Polytechnic, PDH, SAMSUNG, Record, Construction, Oil, S.A

The USD 2 billion project comprises a chemicals complex that will be built in the industrial zone of the General Authority for the Suez Canal Economic Zone (SCZONE) in Egypt.

Key Points: 
  • The USD 2 billion project comprises a chemicals complex that will be built in the industrial zone of the General Authority for the Suez Canal Economic Zone (SCZONE) in Egypt.
  • The firms were selected based on a thorough evaluation process which included strict criteria and a scoring system.
  • The project is in line with the Egypts plans to promote foreign direct investment, which has increased significantly in recent months.
  • Gulf states have pledged more than USD 22 billion to support the Egyptian economy, including billions in industrial projects.

Aramis Biosciences Launches to Address Unmet Needs in Ocular Immunology

Retrieved on: 
Wednesday, December 15, 2021
Leonardo S.p.A., San Francisco Bay Area, Nerve growth factor, Acquisition, NASDAQ, Inflammation, Oceana, Salix Pharmaceuticals, Takeda, CMC, FDA, Massachusetts Institute of Technology, Intelligence, Duane syndrome, IND, Perrigo, Drug development, Transplant, GLOBE, Partnership, U.S. FDA, Aramis, Bausch Health, Shire (pharmaceutical company), Harvard University, Science, K.V.N. Naik S.P. Sanstha's Polytechnic, CEO, Research, ISCB Senior Scientist Award, Associate, Ear, Regeneration, Schepens Eye Research Institute, Royal College of Surgeons, Immunology, New Drug Application, Endo International, Élan, University, Harvard Medical School, Royal college, Technology transfer, Richard Roberts (pharmaceutical executive), Patient, Leadership, Department, COO, Technology, Pharmaceutical industry, Ophthalmology

BOSTON, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Aramis Biosciences, Inc., a clinical-stage immuno-ophthalmology biopharmaceutical company, today announced its launch and the completion of a $10.5 million Series A financing led by Safar Partners with a strategic investment from a global leader in ophthalmic pharmaceuticals. Proceeds from the financing will be used to advance the company’s pipeline, including its lead product candidate, A197, a novel, first-in-class, topical immunomodulatory agent licensed from Dompé farmaceutici, through Phase II clinical proof of concept for the treatment of dry eye disease.

Key Points: 
  • Aramis Biosciences was founded by leading experts in the fields of corneal disorders, ocular inflammation and immunology, Reza Dana, M.D., M.P.H., M.Sc.
  • Aramis Biosciences was founded to address this treatment gap with A197, a new molecular entity promising a rapid onset of action, a durable, disease-modifying effect and a clean tolerability profile, said Reza Dana, M.D., M.P.H., M.Sc., Scientific Co-Founder of Aramis Biosciences.
  • Through its exclusive global license agreement, Aramis Biosciences has secured from Domp the global ophthalmic rights to this novel, first-in-class, topical immunomodulatory agent.
  • Aramis Biosciences is a clinical-stage immuno-ophthalmology biopharmaceutical company committed to the development of disease-modifying therapy for ocular surface disease.

Bracco Group Presents The Beauty of Imaging

Retrieved on: 
Thursday, November 4, 2021
Safety, Research, Biotechnology, Italy Pavilion at Epcot, Diagnosis, Technology, Prognosis, LED, Group, Knowledge, Molecular biology, THE, Patient, K.V.N. Naik S.P. Sanstha's Polytechnic, Google Images, Intelligence, Medicine, CEO, Multimedia, Awareness, Health, ITALY, GDP, Expo 2020, Medical device

DUBAI, United Arab Emirates, Nov. 4, 2021 /PRNewswire/ -- The future starts here. As Official Gold Sponsor of the Italy Pavilion, Bracco has brought to Dubai the Italian model of research and innovation in the life sciences sector, presenting cutting-edge solutions in the field of health, safety and prevention, taking the application of artificial intelligence to diagnostic imaging as a starting point. "The integration of molecular biology, biotechnology and digital is revolutionising medicine. Italy is a pulsating hub of this revolution, with its widespread network across the country of authoritative public and private research facilities and innovative companies. The latter are the real spearhead of our industrial system and account for over 10% of GDP", stated Diana Bracco, President and CEO of the Group. In 2015, she was also President of Expo 2015 S.p.A. and Commissioner-General of the Italy Pavilion. "Medicine is now more and more personalised, not only in terms of diagnosis, but also prognosis and the provision of the most effective treatment for individual patients. Bracco is therefore investing heavily in digital innovation, in artificial intelligence tools to analyse radiology imaging. The relationship between health, medicine and technology", she continued, "is destined to become ever closer, and the progressive hybridisation of knowledge will bring about the transition to '4P Medicine': predictive, preventive, participatory and personalised".

Key Points: 
  • The latter are the real spearhead of our industrial system and account for over 10% of GDP", stated Diana Bracco , President and CEO of the Group.
  • Bracco is therefore investing heavily in digital innovation, in artificial intelligence tools to analyse radiology imaging.
  • The Beauty of Imaging is 4 metres tall and consists of 82 screens, divided into 225 ultra-high-definition LED tiles.
  • The Beauty of Imaging installation can be visited at the Italy Pavilion at Expo 2020 Dubai, taking place from 1 October 2021 to 31 March 2022.